These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6795287)

  • 1. The multimeric distribution of factor VIII-related antigen studied by an improved crossed-immunoelectrophoresis technique.
    Lamb MA; Reisner HM; Cooper HA; Wagner RH
    J Lab Clin Med; 1981 Nov; 98(5):751-63. PubMed ID: 6795287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
    Vukovich TC
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gel filtration patterns of factor VIII coagulant antigen and factor VIII related antigen in normal and von Willebrand's disease.
    Chediak J; Peake I; Bloom A
    Thromb Haemost; 1983 Aug; 50(2):509-12. PubMed ID: 6415844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative VIIIR: AG function screening of multiple samples by two-dimensional crossed immunoelectrophoretic technique.
    Enayat MS; Hill FG
    Med Lab Sci; 1982 Oct; 39(4):357-62. PubMed ID: 6817018
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willbrand's disease.
    Mikami S; Takahashi Y; Nishino M; Okubo Y; Fukui H
    Thromb Haemost; 1981 Jun; 45(3):272-5. PubMed ID: 6792740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
    Meyer D; Obert B; Pietu G; Lavergne JM; Zimmerman TS
    J Lab Clin Med; 1980 Apr; 95(4):590-602. PubMed ID: 6965697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of factor VIII related protein synthesized by human endothelial cell: a study of structure and function.
    Chan V; Chan TK
    Thromb Haemost; 1982 Oct; 48(2):177-81. PubMed ID: 6817445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variant von Willebrand's disease. A study emphasizing crossed-immunoelectrophoresis.
    Green D; Philip KJ
    Thromb Haemost; 1980 Feb; 43(1):2-5. PubMed ID: 6967636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.